SAB Biotherapeutics (SABS) Competitors $1.82 -0.13 (-6.67%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.78 -0.05 (-2.47%) As of 02/21/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SABS vs. FBIO, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Fortress Biotech Curis Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk. Is SABS or FBIO more profitable? Fortress Biotech has a net margin of -84.53% compared to SAB Biotherapeutics' net margin of -1,450.14%. Fortress Biotech's return on equity of 0.00% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics-1,450.14% -94.37% -67.26% Fortress Biotech -84.53%N/A -34.93% Do institutionals and insiders hold more shares of SABS or FBIO? 7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 26.5% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 33.4% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer SABS or FBIO? SAB Biotherapeutics currently has a consensus target price of $12.40, suggesting a potential upside of 581.32%. Fortress Biotech has a consensus target price of $13.67, suggesting a potential upside of 743.62%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SABS or FBIO? In the previous week, SAB Biotherapeutics' average media sentiment score of 0.00 equaled Fortress Biotech'saverage media sentiment score. Company Overall Sentiment SAB Biotherapeutics Neutral Fortress Biotech Neutral Does the MarketBeat Community believe in SABS or FBIO? Fortress Biotech received 298 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 82.86% of users gave SAB Biotherapeutics an outperform vote while only 63.62% of users gave Fortress Biotech an outperform vote. CompanyUnderperformOutperformSAB BiotherapeuticsOutperform Votes2982.86% Underperform Votes617.14%Fortress BiotechOutperform Votes32763.62% Underperform Votes18736.38% Which has better valuation & earnings, SABS or FBIO? SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSAB Biotherapeutics$2.24M7.50-$42.19MN/AN/AFortress Biotech$84.51M0.53-$60.64M-$3.05-0.53 Which has more risk and volatility, SABS or FBIO? SAB Biotherapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. SummaryFortress Biotech beats SAB Biotherapeutics on 9 of the 13 factors compared between the two stocks. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.80M$3.12B$5.77B$8.95BDividend YieldN/A1.57%4.78%3.85%P/E RatioN/A30.1126.4618.81Price / Sales7.50319.76449.1576.64Price / CashN/A183.5344.0437.47Price / Book0.293.567.634.64Net Income-$42.19M-$71.72M$3.18B$245.69M7 Day Performance-8.08%-2.45%-1.82%-2.63%1 Month Performance-50.41%0.36%0.22%-2.37%1 Year Performance-64.80%-11.50%17.49%13.65% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics2.3679 of 5 stars$1.82-6.7%$12.40+581.3%-64.8%$16.80M$2.24M0.00140FBIOFortress Biotech1.9017 of 5 stars$1.71-2.8%$13.67+699.2%-6.4%$47.20M$84.51M-0.56170CRISCuris2.7996 of 5 stars$3.22+2.5%$23.00+614.3%-69.9%$27.27M$10.02M-0.4160Upcoming EarningsGap UpBOLTBolt Biotherapeutics3.142 of 5 stars$0.50+2.8%$3.50+597.5%-56.8%$19.20M$7.88M-0.2990MTEMMolecular TemplatesN/A$0.00+66.7%N/A-100.0%$3,000.00$57.31M0.00260Gap UpAMGNAmgen4.4702 of 5 stars$291.16-2.0%$314.09+7.9%+6.9%$156.51B$33.42B38.5626,700Insider TradePositive NewsGILDGilead Sciences4.7808 of 5 stars$104.08-1.8%$101.33-2.6%+50.2%$129.71B$27.12B1,156.4418,000Analyst UpgradeInsider TradeOptions VolumeAnalyst RevisionPositive NewsVRTXVertex Pharmaceuticals4.1116 of 5 stars$459.00-0.8%$505.57+10.1%+15.4%$118.21B$9.87B-230.655,400Analyst DowngradeInsider TradeAnalyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.6169 of 5 stars$673.60-0.1%$973.13+44.5%-26.5%$74.02B$14.20B17.6013,450Dividend AnnouncementALNYAlnylam Pharmaceuticals4.5007 of 5 stars$256.45-3.2%$299.43+16.8%+61.9%$33.08B$1.83B-97.882,100Analyst ForecastInsider TradeBIIBBiogen4.7446 of 5 stars$137.33-0.8%$211.96+54.3%-36.4%$20.01B$9.84B12.417,570Analyst Forecast Related Companies and Tools Related Companies FBIO Competitors CRIS Competitors BOLT Competitors MTEM Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SABS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
